Prinzmetal Angina Therapeutics Market Snapshot (2023 to 2033)

The global prinzmetal angina therapeutics market is expected to surpass an impressive valuation of USD 10.7 Billion in 2023 and is projected to reach USD 17.2 Billion by 2033, trailing a CAGR of 4.85%. A major driving factor is a rise in the patient population suffering from cardiac disorders such as coronary heart disease.

For instance, as per the data published by the World Health Organization, in December 2020, ischemic heart disease was the world's leading cause of death, accounting for around 16 percent of all deaths. This disease has shown the highest increase in deaths since 2000, increasing by more than 2 million to 8.9 million deaths in 2020.

Stroke and chronic obstructive pulmonary disease (COPD) are the second and third largest causes of death, accounting for around 11% and 6% of all deaths, respectively. In addition, an article titled "Angina: contemporary diagnosis and management" published in PubMed Central, in February 2020, stated that Ischemic heart disease (IHD) continues to be the largest cause of death and lost life years in adults, particularly among women under the age of 55.

Angina pectoris is a typical clinical manifestation of IHD and is chest discomfort caused by a heart attack. Therefore, the rising number of patients suffering from IHD is likely to impel the market growth for angina pectoris drugs over the forecast period, thereby driving market growth. However, the growing adoption of minimally invasive surgeries and side effects associated with certain drug classes are some of the factors that may restrain the market's growth in the coming years.

For instance, as per a study titled "Long COVID-19 and microvascular disease-related angina" published in Sociedad Española de Cardiología, in November 2021, after meticulous evaluation and exclusion of other illnesses, the researchers found that 27.1% of the patients evaluated in a long COVID-19 unit had chest pain, some of which was suggestive of angina. A total of 186 patients were enrolled in the trial, 51 (27%) of whom reported ongoing chest pain after being examined in the long COVID-19 unit.

Thus, such studies highlighted the need for drugs to manage angina pectoris in COVID-19 patients, ultimately boosting the demand for targeted drugs. Therefore, the rising number of COVID-19 patients with cardiological complications is likely to boost the market's growth over the forecast period.

Furthermore, factors driving the market growth include the rising burden of lifestyle diseases, especially cardiac disorders; technological advancements towards personalized cardiovascular medicine; and the advancement in novel drug delivery systems.

Report Attribute Details
Expected Market Value (2023) USD 10.7 Billion
Anticipated Forecast Value (2033) USD 17.2 Billion
Projected Growth Rate (2023 to 2033) CAGR 4.85%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Prinzmetal Angina Therapeutics Demand Analysis vs. Forecast 2023 to 2033

The prinzmetal angina therapeutics market was valued at USD 9.08 Billion in 2018 while growing at a CAGR of 2.65% during the historical period. The advent of Novel target drugs and therapies gaining traction like Factor Xa Inhibitors, monoclonal antibodies, and gene therapy are boosting the therapeutics market.

Considering these factors, the Prinzmetal Angina therapeutics market is projected to reach USD 17.2 Billion, while exhibiting a CAGR of 4.85% during the forecast period.

Which are Some Prominent Drivers of the Prinzmetal Angina therapeutics Market?

Emerging therapies to propel market growth

New therapies entering the market will be the main drivers of growth, with one gene-based therapy, Generx (Ad5FGF-4), and two cell-therapy treatments, CLBS16 and CLBS14 anticipated to launch in the US during the forecast period. Other major drivers for the angina market are the aging global population, enhanced survival after an MI, and the rising prevalence of obesity, diabetes, and hypertension. Moreover, diagnosed cases of prinzmetal angina will grow at a CAGR of 16.5% during the forecast period which will directly benefit market expansion.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

High cost of treatment to restrain product demand

The high cost associated with the treatment and the regular uncertainty seen in reimbursement policies are the factors expected to restrict Prinzmetal Angina therapeutics market growth. A rise in concerns regarding side effects on the body is projected to challenge the Prinzmetal Angina market in the forecast period of 2023 to 2033.

On the other hand, non-adherence to cardiovascular medications has been observed among patients with cardiovascular diseases buying generic medicines instead of specific branded drugs is anticipated to hamper the market growth.

Region-Wise Insights

North America dominating the industry for Prinzmental Angina therapeutics

North America dominates the angina pectoris drugs market with a market share of around 42%, due to the established healthcare infrastructure, rising adoption of therapeutics, and the presence of key manufacturers in the USA, which is responsible for its large share. Ischemic heart disease is a major cause of death and disability within the North American region, while angina represents its most common symptom.

For instance, as per the data published by the National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, in February 2022, the most frequent type of heart disease, ischemic heart disease, claimed around 360,900 individual lives in 2020. Coronary artery disease affects approximately 18.2 million persons aged 20 and older. Adults under the age of 65 account for about 2 out of every 10 deaths due to coronary artery disease.

Similarly, an article titled "Ischemic Heart Disease: Noninvasive Imaging Techniques and Findings" published in RSNA (RadioGraphics), in May 2021, stated that in the United States alone, the annual incidence of new coronary events is around 720,000 instances, and the current prevalence of ischemic heart disease is around 18.3 million cases.

Thus, such a higher prevalence of heart disease is likely to increase the incidence of angina pectoris, thereby fueling demand for angina pectoris drugs within the region. Moreover, the rise in the number of clinical trials is also fueling the market's growth. For instance, as of April 2022, there were 23 active and recruiting clinical trials for angina pectoris within the United States. Therefore, these factors together contribute to the expansion of the angina pectoris drug market throughout the analysis period.

The USA dominated the region by accounting for more than 40% of the market share in 2022. Established healthcare infrastructure, growing adoption of therapeutics, and presence of key manufacturers are responsible for its larger share. Also, the rising incidence of cardiac disorders due to a sedentary lifestyle and favorable regulatory initiatives are propelling the market growth.

Changing regulatory scenario in the USA is expected to impact clinical trials of Advanced Therapy Medicinal Products. Multiple gene therapy products in Phase II/III trials are emerging as a novel approach toward addressing the need for non-surgical cardiovascular treatments. Taxus Cardium’s adenovector (serotype 5) DNA-based gene therapy is currently undergoing late-stage clinical trials and could present promising growth opportunities for the market in the forecast period.

South Asia to be the fastest expanding market for Prinzmetal Angina therapeutics

South Asia is estimated to be the fastest growing region for the angina market owing to the presence of developing economies such as India and China and a developing healthcare sector. This region is projected to witness growth with a CAGR of 4%. Increasing healthcare expenditure and favorable government policies are also anticipated to boost Angina's Market growth during the forecast period.

China offers robust opportunities for market expansion due to the removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform, and supportive 12th Five-Year Plan measures that target biotechnology as a key development sector. Furthermore, the presence of a large target population and robust unmet clinical needs are some of the factors that are expected to fuel growth in this region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

Beta-blockers expected to dominate the segment by drug class

In patients with stable angina caused by CAD, beta-blockers are considered first-line therapy. The segment's growth is majorly attributed to an increase in the target population and a rising number of strategic developments among market players for increasing the commercial availability of beta-blocker drugs.

For instance, in April 2022, New American Therapeutics provided Melinta Therapeutics with the right to TOPROL-XL (metoprolol succinate) in the United States. TOPROL-XL is a cardio-selective beta-blocker that has been approved by the FDA for the treatment of hypertension, either alone or in combination with other antihypertensives, as well as the long-term treatment of angina pectoris and the treatment of stable, symptomatic heart failure of specific causes. Such developments will strengthen the segment's growth in the forecast period.

Hospital Pharmacies expected to dominate the market by distribution channel

The hospital Pharmacies segment is projected to account for a segment share of 55% during the forecast period. This is mostly due to an increase in the number of patients with illnesses that require treatment in hospitals with modern infrastructure and suitable amenities. Furthermore, the expanding number of hospitals, as well as sufficient reimbursement rules, are both contributing to the segment's growth.

Start-ups in Prinzmetal Angina Therapeutics Market

  • Founded in 2018, ‘Echopoint Medical’ is a London-based developer of smart devices for monitoring coronary artery disease and microvascular dysfunction. The company is involved in the development of optical-fiber-based sensors that integrate into medical devices for monitoring cardiac health. It has developed iKOs microcatheter device that uses nanomaterials and sensors that can be positioned into cardiovascular devices for detecting heart conditions by using iKOR technology. Other products include IKOs imaging devices, iKOs 3D tracking devices, and more. It received funding of USD 4 million from Parkwalk, UCL Technology Fund, Gov. UK, and 1 Other Investor.
  • Founded in 2015, ‘Angionetics’, a US-based start-up, is a subsidiary of Texas Cardium Pharmaceuticals Group. It is focused on the late-stage clinical development and commercialization of Generx, an angiogenic gene therapy for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate utilizes a serotype 5 adenovirus (Ad5) to deliver the FGF-4 transgene into heart cells. The Generx product candidates are engineered to express FGF-4, a member of the fibroblast growth factor family.
  • Founded in 2016, ‘Cleerly’ is a Provider of image-driven cardiac health assessment platform. It offers an AI-based diagnostic technology that characterizes and quantifies atherosclerotic plaque in the arteries based on coronary CT angiograms. It enables healthcare providers to diagnose, improves the health outcomes of employees, and provides personalized care. It was granted funding of USD 472 million from Fidelity Investments, T. Rowe Price, and 12 others.

Market Competition

Key players in the prinzmetal angina therapeutics market are: Sanofi S.A., Gilead Sciences; Inc., AstraZeneca Plc, Pfizer; Inc., Eli Lilly, and Company, Amgen; Inc., GlaxoSmithKline Plc, Tasly Pharmaceuticals; Inc., Novartis AG, XyloCor Therapeutics

Some recent developments in this industry are:

  • In March 2022, Zydus Lifesciences received approval from the United States Food and Drug Administration (FDA) to market its Nitroglycerin Sublingual Tablets in the strengths of 0.3 mg, 0.4mg, and 0.6mg (US RLD: Nitrostat Sublingual Tablets) for angina.
  • In October 2021, BioCardia, Inc. announced the treatment of the patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with refractory angina.

Report Scope

Report Attribute Details
Market Value in 2023 USD 10.7 Billion
Market Value in 2033 USD 17.2 Billion
Growth Rate CAGR of 4.85% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered Drug Class, Disease Type, Distribution Channel, Region
Regions Covered North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa
Key Countries Profiled USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, China, Japan, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, United Arab Emirates(UAE), GCC Countries, South Africa, Israel
Key Companies Profiled Sanofi S.A.; Gilead Sciences Inc.; AstraZeneca Plc; Pfizer Inc.; Eli Lilly and Company; Amgen Inc.; GlaxoSmithKline Plc; Tasly Pharmaceuticals Inc.; Novartis AG; XyloCor Therapeutics
Customization Available Upon Request

Key Segments Profiled in the Prinzmetal Angina Therapeutics Market Industry Survey

By Drug Class:

  • Beta Blockers
  • Calcium Antagonists
  • Anti-coagulants
  • Anti-Platelets
  • Anti-Anginal
  • ACE Inhibitors
  • Nitrates

By Disease Type:

  • Stable or Chronic Angina
  • Unstable Angina
  • Variant and Microvascular Angina

By Distribution Channel:

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Estimated Market Growth Rate until 2033?

The market is estimated to rise at a 4.85% CAGR through 2033.

Who are the Top 3 Market Players?

The top 3 market players are Sanofi S.A., Gilead Sciences; Inc., and AstraZeneca Plc,

What Drives Prinzmetal Angina Therapeutics Market Growth?

The emergence of novel therapies propels market growth.

What is the Present Market Value in 2023?

The market is valued at US$ 10.7 billion in 2023.

How Big will be the Market in 2033?

The market is expected to reach US$ 17.2 billion by 2033.

Table of Content
	1. Executive Summary
	2. Market Overview
	3. Market Background
	4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
	5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
		5.1. Beta Blockers
		5.2. Calcium Antagonists
		5.3. Anti-coagulants
		5.4. Anti-Platelets
		5.5. Anti-Anginal
		5.6. ACE inhibitors
		5.7. Nitrates
	6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
		6.1. Stable or chronic angina
		6.2. Unstable angina
		6.3. Variant and microvascular angina
	7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
		7.1. Online pharmacies
		7.2. Hospital pharmacies
		7.3. Retail pharmacies
	8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
		8.1. North America
		8.2. Latin America
		8.3. Europe
		8.4. South Asia
		8.5. East Asia
		8.6. Oceania
		8.7. Middle East and Africa (MEA)
	9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	16. Key Countries Market Analysis
	17. Market Structure Analysis
	18. Competition Analysis
		18.1. Sanofi S.A.
		18.2. Gilead Sciences, Inc.
		18.3. AstraZeneca Plc
		18.4. Pfizer, Inc.
		18.5. Eli Lilly and Company
		18.6. Amgen, Inc.
		18.7. GlaxoSmithKline Plc.
		18.8. Tasly Pharmaceuticals, Inc.
		18.9. Novartis AG
		18.10. XyloCor Therapeutics
	19. Assumptions & Acronyms Used
	20. Research Methodology
Recommendations

Healthcare

Prosthetic Heart Valve Market

October 2023

REP-GB-666

314 pages

Healthcare

Dual Balloon Angioplasty Catheter Market

August 2023

REP-GB-4991

315 pages

Healthcare

Cardiac Assist Devices Market

June 2023

REP-GB-467

315 pages

Healthcare

Heart Block Therapeutics Market

June 2022

REP-GB-15097

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Prinzmetal Angina Therapeutics Market

Schedule a Call